Related references
Note: Only part of the references are listed.p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies
Naveena Singh et al.
JOURNAL OF PATHOLOGY (2020)
Clinicopathological and molecular characterisation of 'multiple-classifier' endometrial carcinomas
Alicia Leon-Castillo et al.
JOURNAL OF PATHOLOGY (2020)
Interpretation of somatic POLE mutations in endometrial carcinoma
Alicia Leon-Castillo et al.
JOURNAL OF PATHOLOGY (2020)
Endometrial Carcinomas with a Serous Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations
Niamh Conlon et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2020)
Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification
Soyoun Rachel Kim et al.
GYNECOLOGIC ONCOLOGY (2020)
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Alicia Leon-Castillo et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility
Martin Kobel et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)
A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples
Sally E. Trabucco et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
LBA63Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy
C L Creutzberg et al.
ANNALS OF ONCOLOGY (2019)
Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists
Robert A. Soslow et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2019)
Blinded histopathological characterisation of POLE exonuclease domain-mutant endometrial cancers: sheep in wolf's clothing
Inge C. Van Gool et al.
HISTOPATHOLOGY (2018)
Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups
Tjalling Bosse et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series
S. Kommoss et al.
ANNALS OF ONCOLOGY (2018)
Adjuvant Treatment for POLE Proofreading Domain-Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Inge C. Van Gool et al.
CLINICAL CANCER RESEARCH (2018)
An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer
Casey M. Cosgrove et al.
GYNECOLOGIC ONCOLOGY (2018)
The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses
Jessica McAlpine et al.
JOURNAL OF PATHOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Practical guidance for mismatch repair-deficiency testing in endometrial cancer
E. Stelloo et al.
ANNALS OF ONCOLOGY (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
Florine A. a Eggink et al.
ONCOIMMUNOLOGY (2017)
Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup
Lien N. Hoang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2017)
Confirmation of ProMisE: A Simple, Genomics-Based Clinical Classifier for Endometrial Cancer
Aline Talhouk et al.
CANCER (2017)
Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy
Salwa Bakhsh et al.
HISTOPATHOLOGY (2016)
Unusual Mismatch Repair Immunohistochemical Patterns in Endometrial Carcinoma
Jaclyn C. Watkins et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab
Alessandro D. Santin et al.
CLINICAL CANCER RESEARCH (2016)
Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis
Melissa K. McConechy et al.
CLINICAL CANCER RESEARCH (2016)
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts
Ellen Stelloo et al.
CLINICAL CANCER RESEARCH (2016)
The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility
Yaser R. Hussein et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2016)
A clinically applicable molecular-based classification for endometrial cancers
A. Talhouk et al.
BRITISH JOURNAL OF CANCER (2015)
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
Ellen Stelloo et al.
MODERN PATHOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations
Yaser R. Hussein et al.
MODERN PATHOLOGY (2015)
Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma
C. Blake Gilks et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Integrated genomic characterization of endometrial carcinoma
Gad Getz et al.
NATURE (2013)
Endometrial cancer incidence trends in Europe: Underlying determinants and prospects for prevention
F Bray et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2005)
Share Paper
